$NUWE·8-K

Nuwellis, Inc. · Jun 17, 5:59 PM ET

Compare

Nuwellis, Inc. 8-K

Research Summary

AI-generated summary

Updated

Nuwellis, Inc. CEO Resigns; Michael McCormick Appointed Effective June 30, 2026

What Happened

  • Nuwellis, Inc. (NUWE) filed an 8-K on June 18, 2026 reporting that John L. Erb resigned as Chief Executive Officer effective June 30, 2026; he will remain Chairman of the board.
  • The board appointed Michael McCormick, age 65, as Chief Executive Officer and President effective June 30, 2026; he will also join the board, increasing its size from five to six members. McCormick has been a consultant to Nuwellis since September 2025 (including serving as Chief Commercial Officer under a consulting arrangement) and previously served as a director from June 2023 to January 2026.

Key Details

  • Employment Agreement: 12-month term beginning June 30, 2026 (may be extended by mutual agreement).
  • Compensation: annual base salary of $431,100 and eligibility for annual incentive targeted at 65% of base salary (prorated for 2026).
  • Equity: a one-time equity grant to be awarded within 90 days of joining; final terms will be determined by the Compensation Committee and board after consulting a third-party compensation consultant. Details required by Item 502(c)(3) are not yet determined; the company will file an amendment within four business days after that information is available.
  • Continuity and background: Erb remains Chairman; McCormick is a veteran medical-device executive (former CEO of Osprey Medical and Anulex, current CEO of CorRen Medical) and serves on multiple industry boards.

Why It Matters

  • Leadership change at the CEO level is material for investors because it affects strategic direction and management continuity; the outgoing CEO remains as Chairman, which can provide continuity at the board level.
  • The new CEO’s compensation package (salary, incentive target and equity award) could affect near-term operating expense and longer-term share dilution depending on the equity terms once disclosed.
  • Investors should watch for the forthcoming amendment with full equity award details and any forward-looking guidance or strategic commentary in related company communications (the company issued a press release dated June 16, 2026, attached as Exhibit 99.1).

Loading document...